Generate Biomedicines (NASDAQ:GENB) Shares Up 7% - What's Next?

Key Points

• Generate Biomedicines (GENB) jumped about 7% on Monday, trading as high as $12.12 and last at $12.21 versus a prior close of $11.41, on markedly lighter volume (≈95,499 shares vs. a 547,054 average).
• Analyst interest has ramped up with multiple initiations/upgrades — six Buy ratings and one Hold — producing a consensus price target of $23.20; notable targets include Guggenheim $30, Piper Sandler $24 and HC Wainwright $16.
• Generate Biomedicines uses machine learning and generative AI to design and optimize proteins and biologic molecules, aiming to accelerate discovery of novel therapeutics.

Generate Biomedicines Inc (NASDAQ:GENB - Get Free Report) shot up 7% on Monday . The stock traded as high as $12.12 and last traded at $12.21. 95,499 shares traded hands during mid-day trading, a decline of 83% from the average session volume of 547,054 shares. The stock had previously closed at $11.41.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on GENB. Guggenheim began coverage on Generate Biomedicines in a report on Tuesday, March 24th. They issued a "buy" rating and a $30.00 price target for the company. Cantor Fitzgerald initiated coverage on Generate Biomedicines in a research note on Tuesday, March 24th. They issued an "overweight" rating for the company. Wall Street Zen upgraded Generate Biomedicines to a "hold" rating in a research note on Saturday, March 14th. Piper Sandler initiated coverage on Generate Biomedicines in a research note on Tuesday, March 24th. They issued an "overweight" rating and a $24.00 price objective for the company. Finally, HC Wainwright started coverage on Generate Biomedicines in a research report on Monday. They set a "buy" rating and a $16.00 price target for the company. Six equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat.com, Generate Biomedicines presently has an average rating of "Moderate Buy" and a consensus price target of $23.20.

Generate Biomedicines Stock Performance

About Generate Biomedicines

Generate Biomedicines, Inc NASDAQ: GENB is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.